<DOC>
	<DOCNO>NCT01023217</DOCNO>
	<brief_summary>The presence persistent inadequate suboptimal virologic response strong risk factor viral resistance breakthrough also disease progression chronic hepatitis B , thus , change therapy require . The combination entecavir ( ETV ) adefovir ( ADV ) promise treatment patient lamivudine ( LAM ) -resistance show suboptimal response combination LAM ADV . In randomized , open label trial , investigator compare efficacy continuation ADV plus LAM versus switch ADV plus ETV adult LAM-resistant chronic hepatitis B show suboptimal response combination treatment ADV LAM .</brief_summary>
	<brief_title>Entecavir Plus Adefovir Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir</brief_title>
	<detailed_description>In randomize , open label , two-arm , single center phase IV trial , investigator assess compare efficacy safety continuation ADV plus LAM versus switch ADV plus ETV 52-weeks Korean adult chronic hepatitis B resistant mutant LAM show suboptimal response combination ADV plus LAM . All study subject complete initial treatment 52-weeks thereafter treat combination ADV plus ETV 52 week . Study period : Nov 2009 - October 2012 Patient enrollment period : November 2009 - December 2010 Study protocol 1 . Group A ( ADV+LAM group ) : Adefovir ( 10 mg/day ) + Lamivudine ( 100 mg/day ) 52 week , thereafter , Adefovir ( 10 mg/day ) + Entecavir ( 1 mg/day ) 52 week 2 . Group B ( ADV+ETV group ) : Adefovir ( 10 mg/day ) + Entecavir ( 1 mg/day ) 104 week</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Male female , 16 75 year age 2 . Compensated liver disease ( ChildPugh class A ) 3 . HBsAg positive least 6 month 4 . HBeAg positive negative 5 . Confirmation Lamivudineresistance HBV mutation anytime study 6 . Patients suboptimal response ( HBV DNA &gt; 2000 IU/mL despite combination Adefovir [ 10 mg/day ] plus Lamivudine [ 100 mg/day ] 6 month ) . Serum HBV DNA determine PCR assay local laboratory screen study 7 . Patient ambulatory . 8 . Patient willing able comply study drug regimen study requirement . 9 . The patient willing able provide write informed consent participate study . 1 . Patient history hepatocellular carcinoma ( HCC ) finding suggestive possible HCC , suspicious focus image study elevate serum alpha fetoprotein ( AFP ) level . In patient finding , HCC ruledout prior randomize patient present study . 2 . Patient previously receive oral antiviral agent Lamivudine Adefovir 3 . Patient receive interferon immunomodulatory treatment HBV infection within 12 month screen study . 4 . Patient concomitant chronic viral infection ( HCV HIV ) 5 . Patient evidence renal insufficiency define serum creatinine &gt; 1.5 mg/dL 6 . Patient medical condition require use systemic prednisolone immunosuppressive agent ( include chemotherapeutic agent ) 7 . Patient currently abuse alcohol illicit drug , history alcohol abuse illicit substance abuse within precede two year . 8 . Patient pregnant breastfeed willing pregnant 9 . Patient one additional know primary secondary cause liver disease , hepatitis B ( e.g. , alcoholism , autoimmune hepatitis , malignancy hepatic involvement , hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's Disease , congenital metabolic condition affect liver , congestive heart failure severe cardiopulmonary disease , etc. ) . 10 . A history treat malignancy ( hepatocellular carcinoma ) allowable patient 's malignancy complete remission , chemotherapy without additional surgical intervention , precede three year . 11 . Clinical sign decompensated liver disease indicate one following : serum bilirubin &gt; 3 mg/dL prothrombin time &gt; 6 second prolonged INR &gt; 1.6 serum albumin &lt; 2.8 g/dL History ascites , variceal hemorrhage , hepatic encephalopathy ChildPugh score â‰¥7</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>lamivudine</keyword>
	<keyword>adefovir</keyword>
	<keyword>entecavir</keyword>
</DOC>